Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1622-1632

  Gerdemann, Ulrike ^a   Keirnan, Jacqueline M ^a   Katari, Usha L ^a   Yanagisawa, Ryu ^a   Christin, Anne S ^a   Huye, Leslie E ^a   Perna, Serena K ^a   Ennamuri, Sravya ^a   Gottschalk, Stephen ^a   Brenner, Malcolm K ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Leen, Ann M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 7; VIRUS ANTIGEN;

ADENOVIRUS; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; BK VIRUS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL POLARITY; CELL SPECIFICITY; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS INFECTION;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 6; RESPIRATORY SYNCYTIAL VIRUS;

EID: 84864547457     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.130     Document Type: Article

References (50)

1. Schönberger, S, Meisel, R, Adams, O, Pufal, Y, Laws, HJ, Enczmann, J et al. (2010). Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16: 1428-1435.
2. Verdeguer, A, de Heredia, CD, González, M, Martínez, AM, Fernández-Navarro, JM, Pérez-Hurtado, JM et al.; GETMON: Spanish Working Party for Blood and Marrow Transplantation in Children. (2011). Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. Bone Marrow Transplant 46: 119-124.
3. Lang, P and Handgretinger, R (2008). Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 42 Suppl 2: S54-S59.
4. Sauter, C, Abboud, M, Jia, X, Heller, G, Gonzales, AM, Lubin, M et al. (2011). Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 17: 1460-1471.
5. Hantz, S, Garnier-Geoffroy, F, Mazeron, MC, Garrigue, I, Merville, P, Mengelle, C et al.; French CMV Resistance Survey Study Group. (2010). Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 65: 2628-2640.
6. Ljungman, P, Ribaud, P, Eyrich, M, Matthes-Martin, S, Einsele, H, Bleakley, M et al.; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. (2003). Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 31: 481-486.
7. Heslop, HE, Brenner, MK and Rooney, CM (1994). Donor T cells to treat EBVassociated lymphoma. N Engl J Med 331: 679-680.
8. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166.
9. Leen, AM, Christin, A, Myers, GD, Liu, H, Cruz, CR, Hanley, PJ et al. (2009). Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114: 4283-4292.
10. Haque, T, Wilkie, GM, Jones, MM, Higgins, CD, Urquhart, G, Wingate, P et al. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
11. Kedl, RM, Rees, WA, Hildeman, DA, Schaefer, B, Mitchell, T, Kappler, J et al. (2000). T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 192: 1105-1113.
12. Kedl, RM, Schaefer, BC, Kappler, JW and Marrack, P (2002). T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 3: 27-32.
13. Cobbold, M, Khan, N, Pourgheysari, B, Tauro, S, McDonald, D, Osman, H et al. (2005). Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386.
14. Feuchtinger, T, Matthes-Martin, S, Richard, C, Lion, T, Fuhrer, M, Hamprecht, K et al. (2006). Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134: 64-76.
15. Feuchtinger, T, Opherk, K, Bethge, WA, Topp, MS, Schuster, FR, Weissinger, EM et al. (2010). Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
16. Khanna, N, Stuehler, C, Conrad, B, Lurati, S, Krappmann, S, Einsele, H et al. (2011). Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 118: 1121-1131.
17. Leen, AM, Sili, U, Savoldo, B, Jewell, AM, Piedra, PA, Brenner, MK et al. (2004). Fibermodified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 103: 1011-1019.
18. Leen, AM, Christin, A, Khalil, M, Weiss, H, Gee, AP, Brenner, MK et al. (2008). Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82: 546-554.
19. Hislop, AD, Taylor, GS, Sauce, D and Rickinson, AB (2007). Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
20. Badr, G, Bédard, N, Abdel-Hakeem, MS, Trautmann, L, Willems, B, Villeneuve, JP et al. (2008). Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 82: 10017-10031.
21. Kannanganat, S, Ibegbu, C, Chennareddi, L, Robinson, HL and Amara, RR (2007). Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to singlecytokine-producing cells. J Virol 81: 8468-8476.
22. Leen, A, Meij, P, Redchenko, I, Middeldorp, J, Bloemena, E, Rickinson, A et al. (2001). Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 75: 8649-8659.
23. Heslop, HE, Ng, CY, Li, C, Smith, CA, Loftin, SK, Krance, RA et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2: 551-555.
24. Gotch, F, McMichael, A, Smith, G and Moss, B (1987). Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 165: 408-416.
25. McMichael, AJ, Gotch, F, Cullen, P, Askonas, B and Webster, RG (1981). The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 43: 276-284.
26. Bunde, T, Kirchner, A, Hoffmeister, B, Habedank, D, Hetzer, R, Cherepnev, G et al. (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036.
27. Bickham, K, Münz, C, Tsang, ML, Larsson, M, Fonteneau, JF, Bhardwaj, N et al. (2001). EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 107: 121-130.
28. Münz, C, Bickham, KL, Subklewe, M, Tsang, ML, Chahroudi, A, Kurilla, MG et al. (2000). Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191: 1649-1660.
29. Balduzzi, A, Lucchini, G, Hirsch, HH, Basso, S, Cioni, M, Rovelli, A et al. (2011). Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46: 987-992.
30. Rock, MT, McKinney, BA, Yoder, SM, Prudom, CE, Wright, DW and Crowe, JE Jr (2011). Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays. J Immunol Methods 374: 13-17.
31. Shao, HY, Lin, YW, Yu, SL, Lin, HY, Chitra, E, Chang, YC et al. (2011). Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse. PLoS ONE 6: e25500.
32. Feuchtinger, T, Richard, C, Joachim, S, Scheible, MH, Schumm, M, Hamprecht, K et al. (2008). Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 31: 199-206.
33. Gerdemann, U, Christin, AS, Vera, JF, Ramos, CA, Fujita, Y, Liu, H et al. (2009). Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 17: 1616-1625.
34. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-935.
35. Kenter, GG, Welters, MJ, Valentijn, AR, Lowik, MJ, Berends-van der Meer, DM, Vloon, AP et al. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838-1847.
36. Maecker, HT, Dunn, HS, Suni, MA, Khatamzas, E, Pitcher, CJ, Bunde, T et al. (2001). Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255: 27-40.
37. Kozlowski, S, Corr, M, Shirai, M, Boyd, LF, Pendleton, CD, Berzofsky, JA et al. (1993). Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J Immunol 151: 4033-4044.
38. Toes, RE, van der Voort, EI, Schoenberger, SP, Drijfhout, JW, van Bloois, L, Storm, G et al. (1998). Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160: 4449-4456.
39. Sherman, LA, Burke, TA and Biggs, JA (1992). Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med 175: 1221-1226.
40. Larsen, SL, Pedersen, LO, Buus, S and Stryhn, A (1996). T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J Exp Med 184: 183-189.
41. Rosenberg, SA, Yannelli, JR, Yang, JC, Topalian, SL, Schwartzentruber, DJ, Weber, JS et al. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166.
42. Becker, TC, Wherry, EJ, Boone, D, Murali-Krishna, K, Antia, R, Ma, A et al. (2002). Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195: 1541-1548.
43. Vella, AT, Dow, S, Potter, TA, Kappler, J and Marrack, P (1998). Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA 95: 3810-3815.
44. Tan, JT, Ernst, B, Kieper, WC, LeRoy, E, Sprent, J and Surh, CD (2002). Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195: 1523-1532.
45. Melchionda, F, Fry, TJ, Milliron, MJ, McKirdy, MA, Tagaya, Y and Mackall, CL (2005). Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 115: 1177-1187.
46. Chetoui, N, Boisvert, M, Gendron, S and Aoudjit, F (2010). Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 130: 418-426.
47. Sportès, C, Babb, RR, Krumlauf, MC, Hakim, FT, Steinberg, SM, Chow, CK et al. (2010). Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 16: 727-735.
48. Majhail, NS, Hussein, M, Olencki, TE, Budd, GT, Wood, L, Elson, P et al. (2004). Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer. Invest New Drugs 22: 421-426.
49. von Rossum, A, Krall, R, Escalante, NK and Choy, JC (2011). Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP(S) expression. J Biol Chem 286: 21137-21144.
50. Maus, MV, Thomas, AK, Leonard, DG, Allman, D, Addya, K, Schlienger, K et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20: 143-148.